| 1.96 -0.04 (-2%) | 11-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.77  |
1-year : | 3.12 |
| Resists | First : | 2.37 |
Second : | 2.67 |
| Pivot price | 2.29 |
|||
| Supports | First : | 1.89 | Second : | 1.58 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.31 |
| MA(100) : | 2.06  |
MA(250) : | 2.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13 |
D(3) : | 14 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 5.05 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INO ] has closed above bottom band by 1.6%. Bollinger Bands are 2.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.05 - 2.06 | 2.06 - 2.07 |
| Low: | 1.87 - 1.88 | 1.88 - 1.89 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Wed, 12 Nov 2025
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress (NASDAQ:INO) - Seeking Alpha
Tue, 11 Nov 2025
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2025 Earnings Call Transcript - Insider Monkey
Tue, 11 Nov 2025
Inovio Pharmaceuticals drops 6%, proposes equity offering - MSN
Tue, 11 Nov 2025
Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Mon, 10 Nov 2025
INOVIO Announces Proposed Public Offering (2025-11-10) - Seeking Alpha
Mon, 10 Nov 2025
Inovio: Q3 Earnings Snapshot - San Francisco Chronicle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.286e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 7,490 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.429e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -52 % |
| Return on Assets (ttm) | 568.6 % |
| Return on Equity (ttm) | -59.3 % |
| Qtrly Rev. Growth | 182340 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -84.41 |
| EBITDA (p.s.) | -3.73795e+007 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 4.17 |
| Dividend | 0 |
| Forward Dividend | 7.58e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|